Sagimet Biosciences, Inc. Class A (SGMT)
NASDAQ:SGMT
Want to see SGMT full AI Analyst Report?
SGMT Stock Chart & Stats
$6.47
-$0.58(-10.41%)
At close: 4:00 PM EST
$6.47
-$0.58(-10.41%)
Day’s Range― - ―
52-Week Range$4.50 - $11.41
Previous CloseN/A
Volume1.06M
Average Volume (3M)839.41K
Market Cap
$395.86M
Enterprise Value$168.68M
Total Cash (Recent Filing)$104.54M
Total Debt (Recent Filing)$39.00K
Price to Earnings (P/E)―
Beta2.87
Next Earnings
Aug 19, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.35
Shares Outstanding61,184,315
10 Day Avg. Volume657,715
30 Day Avg. Volume839,411
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)1.72
Price to Sales (P/S)0.00
P/FCF Ratio-4.19
Enterprise Value/Market Cap0.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.66
Forecast
1Y Price Target
$26.09Price Target Upside303.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-1.2
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage, Solid Balance SheetExtremely low debt and a positive equity base provide structural financial flexibility, reducing insolvency risk and preserving optionality to fund trials or partnerships. This durability supports multi-quarter development programs and strategic negotiating leverage with partners or acquirers.
Material Equity Financing To Fund PipelineA ~$164.5M underwritten offering materially extends funded runway, enabling planned U.S. Phase 3 trials and multiple development programs. This capital reduces near-term liquidity uncertainty and allows execution of milestone-driven development plans without immediate revenue generation.
Clinical And Regulatory Validation For Lead AssetPositive Phase 3 data and NMPA NDA acceptance represent tangible clinical validation and a de-risking event for the lead program. These outcomes strengthen the IP-backed franchise, support regulatory credibility, and improve the odds of near-term commercial or partnership pathways.
Bears Say
Negative Free Cash Flow And Cash BurnSustained negative operating cash flow and sizable FCF deficits indicate the business cannot self-fund development. Over multiple quarters this burn necessitates external financing or partner deals, increasing execution risk if capital markets or deal windows narrow.
Ongoing Operating Losses, Minimal RevenueLimited revenues and persistent operating losses underscore that value creation depends on future trial success or partnerships. Continued negative earnings compress equity returns and mean shareholder value is highly contingent on binary clinical/regulatory outcomes.
Reliance On External Capital / Dilution RiskThe company’s development pace and negative cash flow require periodic capital raises, which dilute existing shareholders and can constrain strategic choices. If trial timelines slip or milestones are delayed, future financings may be more dilutive or harder to secure.
Sagimet Biosciences, Inc. Class A News
SGMT FAQ
What was Sagimet Biosciences, Inc. Class A’s price range in the past 12 months?
Sagimet Biosciences, Inc. Class A lowest stock price was $4.50 and its highest was $11.41 in the past 12 months.
What is Sagimet Biosciences, Inc. Class A’s market cap?
Sagimet Biosciences, Inc. Class A’s market cap is $395.86M.
When is Sagimet Biosciences, Inc. Class A’s upcoming earnings report date?
Sagimet Biosciences, Inc. Class A’s upcoming earnings report date is Aug 19, 2026 which is in 63 days.
How were Sagimet Biosciences, Inc. Class A’s earnings last quarter?
Sagimet Biosciences, Inc. Class A released its earnings results on May 12, 2026. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.371 by $0.041.
Is Sagimet Biosciences, Inc. Class A overvalued?
According to Wall Street analysts Sagimet Biosciences, Inc. Class A’s price is currently Undervalued.
Does Sagimet Biosciences, Inc. Class A pay dividends?
Sagimet Biosciences, Inc. Class A does not currently pay dividends.
What is Sagimet Biosciences, Inc. Class A’s EPS estimate?
Sagimet Biosciences, Inc. Class A’s EPS estimate is -0.25.
How many shares outstanding does Sagimet Biosciences, Inc. Class A have?
Sagimet Biosciences, Inc. Class A has 61,184,315 shares outstanding.
What happened to Sagimet Biosciences, Inc. Class A’s price movement after its last earnings report?
Sagimet Biosciences, Inc. Class A reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.371. Following the earnings report the stock price went down -0.52%.
Which hedge fund is a major shareholder of Sagimet Biosciences, Inc. Class A?
Currently, no hedge funds are holding shares in SGMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sagimet Biosciences, Inc. Class A Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.09 (303.26% Upside)
$26.09 (303.26% Upside)
Blogger Sentiment
Bullish
SGMT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.76%
12-Months-Change
Fundamentals
Return on Equity
-37.57%
Trailing 12-Months
Asset Growth
-26.28%
Trailing 12-Months
Company Description
Sagimet Biosciences, Inc. Class A
Sagimet Biosciences Inc. is a biopharmaceutical company with drug candidates in clinical trials, specializing in developing therapies that target fatty acid synthase (FASN) inhibition. These treatments are engineered to combat medical conditions stemming from impaired lipid metabolism pathways. Its primary investigational compound, Denifanstat, is a FASN inhibitor currently being evaluated for nonalcoholic steatohepatitis (NASH) and acne. Additionally, Sagimet is advancing TVB-3567, another FASN inhibitor, which targets various forms of cancer. Founded in 2006, the company's main operations are located in San Mateo, California. It was formerly recognized as 3-V Biosciences, Inc. until it rebranded to Sagimet Biosciences Inc. in August 2019.
SGMT Stock 12 Month Forecast
Average Price Target
$26.09
▲(303.26% Upside)
Technical Analysis
Codexis
―
Cabaletta Bio
―
Black Diamond Therapeutics
―
Atea Pharmaceuticals
―
Entrada Therapeutics Inc
―
Ownership Overview
5.49% Insiders
3.17% Mutual Funds
8.23% Other Institutional Investors
79.48% Public Companies and Individual Investors